The invention relates to a pharmaceutical composition comprising a compound selected from the group consisting of desethylamiodarone and pharmaceutically acceptable salts, hydrates and solvates thereof, together with pharmaceutically acceptable excipients, vehicle and/or carrier, as well as the pharmaceutical composition for use in the treatment and prevention of atrial fibrillation with fewer side effects than its parent compound.